How to Prepare a Biological Evaluation Strategy for a 2026 Submission

# How to Prepare a Biological Evaluation Strategy for a 2026 Submission As medical device technology advances, regulatory expectations for ensuring patient safety evolve in parallel. For manufacturers planning a submission in 2026, particularly for devices with long-term tissue or blood contact, a modern, risk-based biological evaluation strategy is no longer optional—it is the standard. Gone are the days of simply following a checklist of standard tests from a table. Instead, agencies like the FDA expect a comprehensive scientific rationale that begins with the device's materials and manufacturing processes and culminates in a robust justification for the entire evaluation. This modern approach, grounded in the principles of ISO 10993-1 and FDA's corresponding guidance, centers on a Biological Evaluation Plan (BEP). The BEP is a thorough risk assessment that proactively integrates chemical characterization data with a toxicological risk assessment (TRA). This allows sponsors to create a more targeted, efficient, and scientifically sound evaluation, potentially reducing the need for extensive in vivo animal testing when appropriately justified. This article provides a detailed framework for developing a comprehensive biocompatibility strategy that aligns with current and future regulatory expectations. ## Key Points * **Risk-Based Approach is Mandatory:** FDA expects a full risk assessment as outlined in ISO 10993-1. A simple checklist approach is insufficient; the strategy must be tailored to the specific device, its materials, manufacturing processes, and intended use. * **Chemical Characterization is Foundational:** Understanding what chemicals could potentially leach from a finished device is a critical first step. Comprehensive extractables and leachables (E&L) testing (per ISO 10993-18) provides the essential data for the subsequent toxicological assessment. * **Toxicological Risk Assessment Justifies Testing Scope:** A TRA (per ISO 10993-17) uses chemical characterization data to evaluate the risk posed by identified leachables. A favorable TRA can provide a powerful scientific justification for reducing or eliminating certain biological tests. * **Leverage Existing Data for Well-Known Materials:** For materials with a long history of safe use, a robust rationale supported by literature, supplier data, and targeted chemical analysis can justify forgoing some traditional biocompatibility tests. The burden of proof rests on the manufacturer. * **Evaluate the Entire Manufacturing Lifecycle:** The biological evaluation must account for all potential leachables, including residuals from processing aids, cleaning agents, and sterilization. The final, finished, sterilized device is the subject of the evaluation. * **Early FDA Engagement De-Risks Your Submission:** For novel devices, new materials, or when proposing a significantly reduced testing plan, using the FDA's Q-Submission program to gain feedback on the Biological Evaluation Plan is a critical strategic step. ## Understanding the Modern Biological Evaluation Plan (BEP) A Biological Evaluation Plan (BEP) is a comprehensive document that outlines the entire strategy for assessing the biocompatibility of a medical device. It is a risk management tool, not merely a list of tests. For a submission in 2026, the BEP should be developed early in the product development lifecycle and serve as a living document that guides the evaluation process. A well-structured BEP typically includes: 1. **Detailed Device Description:** Including the intended use, patient population, and the nature and duration of body contact. 2. **Complete Material Identification:** A list of every material in the patient-contacting components of the device. 3. **Manufacturing Process Overview:** A description of all manufacturing steps, including molding, machining, cleaning, and sterilization, with a focus on materials and chemicals used. 4. **Initial Risk Assessment:** An analysis based on existing knowledge of the materials and processes to identify potential biological risks (e.g., cytotoxicity, sensitization, systemic toxicity). 5. **Evaluation Strategy:** A detailed plan outlining the proposed approach, which may include: * Leveraging existing literature and material data. * A plan for chemical characterization (E&L) testing. * The plan to conduct a toxicological risk assessment. * A list of any proposed biological tests (e.g., cytotoxicity, hemocompatibility) with justifications. * Scientific rationales for forgoing any standard tests recommended by ISO 10993-1. ## Step-by-Step: Building a Risk-Based Biocompatibility Strategy Developing a robust, risk-based strategy is a systematic process. The goal is to build a logical argument, supported by data, that demonstrates the biological safety of the device. ### Step 1: Characterize the Device and Categorize Contact First, precisely define the device's intended use according to ISO 10993-1. This involves categorizing it based on two factors: * **Nature of Body Contact:** (e.g., surface device, externally communicating device, implant device) * **Duration of Contact:** (e.g., Limited ≤ 24 hours, Prolonged > 24 hours to 30 days, Permanent/Long-term > 30 days) This categorization determines the biological endpoints that must be evaluated (e.g., cytotoxicity, systemic toxicity, implantation). ### Step 2: Gather All Material and Manufacturing Information This is the data-gathering phase. Sponsors should compile a complete file for every component that has direct or indirect patient contact. This includes: * **Material Composition:** Exact chemical makeup, including any additives, colorants, or processing aids. * **Supplier Documentation:** Material safety data sheets (MSDS), technical data sheets, and any available master files. * **Manufacturing Inputs:** A list of all substances used during manufacturing, such as cleaning agents, mold release agents, cutting fluids, and adhesives. * **Sterilization Method:** Details on the sterilization process (e.g., Ethylene Oxide, gamma, steam) and potential residuals. ### Step 3: Conduct Chemical Characterization (Extractables & Leachables) This is the cornerstone of the modern approach. The goal is to identify and quantify the substances that could be released from the device during clinical use. This is typically done through extractables and leachables (E&L) testing, following ISO 10993-18. * **Extractables:** Compounds that are forced out of the device under exaggerated conditions (e.g., aggressive solvents, high temperatures). This provides a worst-case profile of what *could* leach out. * **Leachables:** Compounds that migrate from the device under simulated real-world use conditions. This provides a more realistic patient exposure profile. The chemical analysis must be sensitive enough to detect trace compounds, and the final report should identify each substance and its concentration. ### Step 4: Perform a Toxicological Risk Assessment (TRA) With the chemical characterization data in hand, a qualified toxicologist performs a TRA in accordance with ISO 10993-17. For each identified chemical leachable, the toxicologist will: 1. **Establish a Tolerable Intake (TI):** Determine the maximum daily dose of the substance that is considered safe, based on extensive literature review of toxicological databases. 2. **Calculate Patient Exposure:** Determine the worst-case patient exposure dose based on the E&L results. 3. **Calculate the Margin of Safety (MOS):** Compare the tolerable intake to the patient exposure dose. A sufficiently large margin of safety indicates the risk associated with that chemical is acceptable. The final TRA report provides a conclusion for each chemical and an overall assessment of the device's toxicological risk. If all identified leachables have an acceptable margin of safety, this report becomes a primary piece of evidence to justify forgoing certain in vivo biological tests. ### Step 5: Finalize the Testing Plan and Document Justifications Based on the TRA, the sponsor can finalize the evaluation strategy. * **If the TRA is favorable:** The sponsor can write a scientific rationale explaining why certain endpoints (e.g., systemic toxicity) have been adequately addressed by the chemical and toxicological assessment, thus making the corresponding animal test unnecessary. Some fundamental tests, like in vitro cytotoxicity, are almost always performed regardless. * **If the TRA is inconclusive or unfavorable:** If a chemical lacks sufficient toxicological data or exceeds its safety margin, direct biological testing for the relevant endpoint (e.g., genotoxicity, chronic toxicity) will likely be required. ## Scenario-Based Approaches ### Scenario 1: A Novel Bioabsorbable Polymer for a Long-Term Orthopedic Implant * **What FDA Will Scrutinize:** The primary concern is the lack of long-term clinical use history. FDA will focus on the material's degradation profile over time, the toxicity of its degradation byproducts, and the potential for chronic toxicity or carcinogenicity. * **Evaluation Strategy:** * **Extensive Chemical Characterization:** This would include accelerated degradation studies to identify and quantify all substances released as the polymer breaks down. * **Comprehensive TRA:** A toxicological assessment of both the base polymer and all identified degradation products is essential. * **Targeted Biological Testing:** It is highly unlikely that testing could be completely waived. The strategy would likely involve a full suite of tests, including cytotoxicity, sensitization, irritation, acute systemic toxicity, subchronic toxicity, genotoxicity, and implantation testing with histopathology at multiple time points to assess the local tissue response as the material degrades. The Q-Submission program would be invaluable for aligning with FDA on this extensive plan. ### Scenario 2: A Catheter Made from Medical-Grade PEEK with a Long History of Safe Use * **What FDA Will Scrutinize:** Even with a well-known material, FDA will scrutinize any changes to the manufacturing process. This includes new suppliers for the raw material, different colorants or additives, new cleaning agents, or a change in sterilization method. The evaluation must prove that these changes have not negatively impacted the device's safety profile. * **Evaluation Strategy:** * **Leverage Existing Data:** The BEP would include a literature review and supplier data confirming the biocompatibility of the base PEEK polymer. * **Focused Chemical Characterization:** E&L testing would be designed to look for process-related contaminants—residuals from the new cleaning agents, leachables from the new colorant, etc. * **Targeted TRA:** The toxicological assessment would focus on the specific compounds identified in the E&L study. * **Justified Reduction in Testing:** If the TRA shows that all process-related leachables are well below safe limits, the sponsor could build a strong scientific justification to waive long-term systemic toxicity and implantation studies. The submission would still likely include in vitro cytotoxicity, sensitization, irritation, and hemocompatibility tests, as these address different biological endpoints. ## Strategic Considerations and the Role of Q-Submission For any device that is complex, uses novel materials, or for which the sponsor intends to propose a significantly reduced testing plan, engaging with the FDA via the Q-Submission program is a critical, de-risking step. A Pre-Submission (Pre-Sub) meeting or written feedback request allows a sponsor to present their complete Biological Evaluation Plan (BEP), including the chemical characterization protocol and the proposed toxicological risk assessment framework. This gives the FDA an opportunity to provide feedback *before* expensive and time-consuming studies are initiated. Gaining alignment on the strategy can prevent significant delays and additional testing requests during the final submission review. ## Finding and Comparing Biocompatibility Testing Services Providers Executing this complex strategy requires a partnership with qualified laboratories and consultants. When selecting a provider for biocompatibility, chemical characterization, and toxicology services, sponsors should look for a partner with: * **ISO 17025 Accreditation:** This ensures the lab meets general requirements for testing and calibration competence. * **Deep Regulatory Experience:** The provider should have a proven track record of successful submissions to the FDA and other regulatory bodies. * **Integrated Services:** A provider who can perform chemical characterization, toxicology, and biological testing under one roof can offer a more cohesive and efficient process. * **Expert Consultation:** The team should include experienced chemists and board-certified toxicologists who can help design the strategy and defend it to regulators. Comparing providers based on their expertise, turnaround times, and communication is crucial for a successful outcome. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When developing a biological evaluation strategy, sponsors should refer to the latest versions of key regulatory documents. While specific guidances are numerous, the foundational principles are contained in: * FDA's guidance on the Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." * FDA's Q-Submission Program guidance. * Regulations under 21 CFR that govern premarket submissions, such as 21 CFR Part 807 for premarket notifications. Sponsors should always consult the FDA website for the most current versions of these and other relevant guidance documents. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*